“We are very pleased with the Court's decision,” said
About
Investor Inquiries: ICR WestwickeMike Piccinino , CFA OrganoIR@westwicke.com Press and Media Inquiries: Organogenesis communications@organo.com
Source:
2024 GlobeNewswire, Inc., source
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.465 USD | +3.14% | +4.89% | -39.73% |
May. 02 | Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis | CI |
Feb. 29 | Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024 |
“We are very pleased with the Court's decision,” said
About
Investor Inquiries: ICR WestwickeMike Piccinino , CFA OrganoIR@westwicke.com Press and Media Inquiries: Organogenesis communications@organo.com
Source:
2024 GlobeNewswire, Inc., source
1st Jan change | Capi. | |
---|---|---|
-39.73% | 317M | |
+21.34% | 46.81B | |
-0.99% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.27% | 26.06B | |
-19.34% | 19.13B | |
+32.10% | 12.39B | |
+0.08% | 12.08B | |
+0.14% | 11.96B |